Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

This study is testing whether olanzapine — a medication typically used for psychiatric conditions but also known to stimulate appetite — can help reverse cancer-related weight loss and poor appetite in people with advanced cancers of the stomach, esophagus, liver, pancreas, bile ducts, colon, or lung. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic cancer of the esophagus, stomach, liver, pancreas, bile ducts, colon/rectum, or lung - You have lost at least 5% of your body weight in the past 6 months, or at least 2% with a low BMI - You are starting or already on first-line palliative cancer treatment - You can walk and move around independently - Your ECOG performance status is 0–2 **You may NOT be eligible if...** - You are past your first cycle of palliative treatment - You have uncontrolled brain metastases or are on corticosteroids for brain swelling - You are taking other medications that could interact with olanzapine - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.